Cargando…
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4...
Autores principales: | Dumontet, Charles, Hulin, Cyrille, Dimopoulos, Meletios A., Belch, Andrew, Dispenzieri, Angela, Ludwig, Heinz, Rodon, Philippe, Van Droogenbroeck, Jan, Qiu, Lugui, Cavo, Michele, Van de Velde, Ann, Lahuerta, Juan José, Allangba, Olivier, Lee, Jae Hoon, Boyle, Eileen, Perrot, Aurore, Moreau, Philippe, Manier, Salomon, Attal, Michel, Roussel, Murielle, Mohty, Mohamad, Mary, Jean Yves, Civet, Alexandre, Costa, Bruno, Tinel, Antoine, Gaston-Mathé, Yann, Facon, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990520/ https://www.ncbi.nlm.nih.gov/pubmed/29784907 http://dx.doi.org/10.1038/s41375-018-0133-x |
Ejemplares similares
-
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022) -
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
por: Facon, Thierry, et al.
Publicado: (2019) -
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018) -
Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023) -
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)